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ORIGINAL ARTICLE
Genetic diversity of Streptococcus pneumoniae causing
meningitis and sepsis in Singapore during the first year of
PCV7 implementation
Elita Jauneikaite1,2, Johanna Mary Carnon Jefferies1,3, Nicholas William Vere Churton1,4, Raymond Tzer Pin Lin5,
Martin Lloyd Hibberd2,6 and Stuart Charles Clarke1,3,7
Streptococcus pneumoniae is a major cause of sepsis, meningitis and respiratory disease worldwide. Pneumococcal conjugate
vaccines (PCVs) have now been implemented inmany countries worldwide, including Singapore. To evaluate the effectiveness of these
vaccines, pneumococcal surveillance studies are required. Detailed and unified pneumococcal epidemiology data are currently scarce
in South East Asia. Thus, we present data on invasive pneumococcal (IPD) isolates from Singapore that could assist in evaluating the
effectiveness of pneumococcal vaccine inSingapore. Onehundred and fifty-nine invasive pneumococcal disease isolateswere received
by the National Public Health Laboratory in Singapore between June 2009 and August 2010. Isolates were characterized using
serotyping and multilocus sequence typing. Twenty-four different serotypes were found, the most common of which were 19A, 3, 7F,
23F, 6B, 14, 8 and 19F (in rank order). One hundred and two sequence types were observed, of which 38 were novel due to new alleles
or new combinations of already existing alleles. Based on the Simpson’s Index of Diversity, serotypes 3, 6B and 19A were the most
genetically diverse. Novel sequence types were more prevalent among conjugate vaccine serotypes 3, 19F and 23F and non-conjugate
vaccine serotype 8, serogroup 15 and in non-typable isolates. We have demonstrated considerable genetic diversity among invasive
pneumococci before and during the widespread use of conjugate vaccines in Singapore. Approximately half of all novel IPD clones
identified in this study were non-conjugate vaccine serotypes. Although PCVs would target the most common serotypes, the high
genetic diversity in non-vaccine serotypes would require further surveillance studies.
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INTRODUCTION
Streptococcus pneumoniae is an important cause of sepsis, meningitis,
pneumonia and otitis media. Invasive pneumococcal disease (IPD) is
responsible for high rates of morbidity and mortality, especially in
young children, the elderly and the immunocompromised. According
to a report by theWorld Health Organization, between 700 000 and one
million children aged less than five years die annually due to pneumo-
coccal infection.1 Pneumococcal pneumonia is considered to be one of
the major causes of childhood mortality in the developing world and of
adult mortality worldwide.2,3
Studies investigating the prevalence of serotypes, genotypes and
antibiotic-resistant pneumococcal isolates in IPD in Singaporean chil-
dren and adult populations were reported previously.4–10 The seven-
valent pneumococcal conjugate vaccine (PCV7)—Prevnar (Pfizer,
New York, USA) covers serotypes 4, 6B, 9V, 14, 18C, 19F and 23F,
and has been available on demand in Singapore since its approval in
200511 and was added to the childhood immunization programme in
October 2009.11–13 Other available pneumococcal vaccines are PCV10—
Synflorix (GlaxoSmithKline, Bentford, UK) that includes PCV7 serotypes
and serotypes 1, 5 and 7F; and pneumococcal polysaccharide vaccine
(PPV-23)—Pneumovax 23 (Merck, New Jersey, USA) which consists
of pure polysaccharides of 23 pneumococcal serotypes (1, 2, 3, 4, 5, 6B,
7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F,
33F). PPV-23 is recommended by Ministry of Health in Singapore for
elderly and people at higher risk of acquiring pneumococcal disease.14 In
December 2011, PCV13—Prevnar 13 (Pfizer) which includes all PCV7
serotypes and the additional six serotypes of pneumococci: 1, 5, 7F, 3, 6A
and 19A—replaced PCV7 in children immunization program in
Singapore. The reported vaccine uptake was low – 21.6% in 2009 and
41% in 2010.15 This calls for further surveillance studies to document the
true changes in prevalence of pneumococcal serotypes and possible vac-
cine serotype replacement by non-vaccine serotypes as it has been
reported in other countries.16 Knowledge of genotypic and serotype data
can also provide information on serotype replacement and vaccine escape
isolates. For example, after PCV7 was implemented in the United States,
an increase in infections caused by serotype 19A was reported.17,18
Undertaking disease surveillance provides baseline data for moni-
toring the impact of a new vaccine.19 This is particularly important for
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pneumococcal disease as PCVs include only a limited number of
known serotypes. Pneumococcal populations undergo temporal
changes in clonal distribution in the absence of pressure from a vac-
cine.8,19 Certain genotypes and serotypes of the pneumococcus may
have a higher invasive potential than others;17,20–22 therefore, an
understanding of underlying population structure is informative for
formulating vaccine policy. Characterizing pneumococci by multilo-
cus sequence typing (MLST) assesses the genetic relatedness of isolates
by comparing the allelic sequences of seven housekeeping genes.23
Here, we present a descriptive epidemiology of the serotype and
sequence type composition of invasive pneumococcal isolates during
the early stages of the PCV7 implementation in Singapore.
MATERIALS AND METHODS
Bacterial isolates
One hundred and fifty-nine S. pneumoniae isolates from cases of IPD
were collected as part of the pneumococcal surveillance program by
theNational Public Health Laboratory in Singapore from June 2009 to
August 2010. One hundred and fifty-seven bacterial isolates (99.3%)
included information on age, gender, date the isolate was received at
the National Public Health Laboratory, serotype and specimen. One
isolate (0.7%) had no information on age and gender. No information
on vaccination status was available except for one isolate (0.7%).
Pneumococcal capsular typing
Capsular typing was carried out by trained laboratory staff using the
Pneumotest kit (Statens Serum Institute, Copenhagen, Denmark) at
National Public Health Laboratory, Singapore. A simplified chess-
board system24 was adopted to determine 21 vaccine-related serotypes
or serogroups. The test was carried out by mixing 4 mL of bacterial
suspension (pure bacterial culture and sterile phosphate buffered sa-
line) with 4 mL of antiserum on a microscope slide. A coverslip was
placed over the suspension and the slide was examined under phase
contrast microscope. A reaction was considered to be positive when
swelling of the capsule or agglutination was seen. Serogroups 6, 7, 9,
18, 19 and 23 were further tested with specific factor antisera to deter-
mine their serotypes. Non-vaccine-related serotypes or serogroups
(not included in the simplified chessboard system) were reported as
non-typable.
All isolates were serotyped in parallel using the polymerase chain
reaction (PCR) method described by the Centre for Disease Control
and Prevention.25
DNA extraction
S. pneumoniae DNA for PCR and MLST sequencing was extracted
from an overnight culture (grown on Columbia blood agar (Oxoid,
Basingstoke, UK), incubated at 37 6C at 5% CO2 incubator) using the
QIAamp DNA mini kit (Qiagen, Hilden, Germany) according to the
manufacturer’s instructions.
Multilocus sequence typing
DNA extractions were sent to Qiagen Sequencing Services for MLST.
Sequence types (STs) were assigned using the MLST website.26 New
alleles and new STs were assigned by the MLST website curator.
Data analysis
Data were analysed based on age of the patient, serotypes and MLST.
MLST data were analysed using goeBURST (PHYLOViZ)27 with para-
meters set for: seven loci per isolate, six identical loci per group and
minimum three single loci variants per subgroup. Simpson’s Index of
Diversity (SID) was calculated as previously described.28
RESULTS
Twelve pneumococcal isolates were from children under the age of five
years; two isolates were from children between 5 and 18 years old; 82
isolates were from adults between 18 and 64 years old and 60 were
from older adults (65 years old and above); one isolate had no age
information. Ninety-four percent of all isolates (n5146) came from
blood samples; the remainder were from cerebrospinal fluid (n54),
pleural (n53) and peritoneal (n52) fluids.
MLST indicated that two of 159 isolates were not S. pneumoniae and
were excluded from further analysis (these two isolates were reported
as non-typable by Pneumotest). Another two isolates did not yield a
full MLST profile; therefore, they were excluded fromMLST analysis.
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Figure 1 Serotype incidence among age groups. Total number of isolates 156. Vaccine coverage would be: PCV—38% (n560, including the cross-protection for
serotype 6A), PCV10—50% (n579) andPCV13—74% (n5116). NT, non-typable by Pneumotest kit ormPCRmethod; UC, uncapsulated (cpsA not present, ply gene
present, MLST indicated S. pneumoniae).
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Serotype distribution
Isolates were assigned to 24 different serotypes and serogroups. The
most common serotypes were serotype 19A (n520), 3 (n518), 7F
(n515; including one isolate with unknown age), 23F (n514), 6B
(n514), 14 (n512), 8 (n510) and 19F (n58) (Figure 1). Serotypes
6B, 19A and 14 were the most common in children under the age of
five years old (Figure 1). The most common serotypes in the adult
group (aged from 18 to 64 years inclusive) were 19A, 3, 7F, 8 and 23F
(Figure 1). Serotypes 3, 19A, 23F, 14 and 7F were most commonly
found in people that were aged 65 years and over (Figure 1).
This serotype data suggest the coverage by PCVs to be: PCV7—38%
(n560, including cross-protection for serotype 6A29), PCV10—50%
Table 1 ST and serotype/serogroup distribution within age groups
Serotype/serogroup ST
Children:f5 years (n512)
Serotype 6B 315 (n51); 2782 (n51); 6198 (n51); unavailable (n51)
Group 11 6191 (n51)
Serotype 14 9 (n51)
Serotype 15B/C 6192 (n51)
Serotype 19A 320 (n52)
Serotype 19F 236 (n51); 320 (n51)
Serotype 23F 311 (n51)
Children: 6–18 years (n52)
Serotype 4 5275 (n51)
Serotype 23F 81 (n51)
Adults: 19–64 years (n582)
Serotype 1 217 (n51); 303 (n51); 5044 (n51); 5254 (n51)
Serotype 3 458 (n53); 505 (n51); 4389 (n51); 6193 (n52); 3805 (n51); 63 (n51)
Serotype 6A 5832 (n51)
Serotype 6B 386 (n51); 1518 (n53); 2779 (n51); 6206 (n51)
Serotype 6C 6209 (n51)
Serotype 7F 218 (n51); 3545 (n55); 5265 (n52); 5441 (n51)
Serotype 8 5039 (n54); 5291 (n51); 6197 (n52)
Serotype 9V 156 (n51)
Serogroup 12 989 (n51)
Serotype 14 9 (n51); 143 (n51); 200 (n51); 876 (n51); 6196 (n51)
Serotype 15A 1591 (n51); 6202 (n51); 6204 (n51)
Serogroup 18F 291 (n51); 2711 (n51)
Serotype 19A 230 (n51); 320 (n52); 416(n53); 847 (n51); 1848 (n51); 2013 (n52); 3781 (n51); 3111 (n51)
Serotype 19F 9 (n51); 5260 (n51); 5278 (n51);3791 (n51); 6199 (n51); 5297 (n51)
Serogroup 20 4901 (n51); 5190 (n51)
Serogroup 22 6194 (n51)
Serotype 23A 338 (n51)
Serotype 23F 81 (n53); 361 (n51); 6195 (n51); 6200 (n52)
Non-typable 6207 (n51); 6210 (n51); 5292 (n51)
Uncapsulated 6201 (n51)
Adults: 65 years and above (n560)
Serotype 3 180 (n52); 4655 (n51); 4909 (n51); 5255 (n51); 5267 (n51); 5299 (n51)
Serotype 4 4127 (n53); 5872 (n51)
Serotype 6A 81 (n52); 5272 (n51)
Serotype 6B 95 (n52); 3114 (n51); 5241 (n51)
Serotype 6C 224 (n51); 5295 (n51)
Serotype 7F 191 (n51); 218 (n51); 3544 (n52); 3545(n51)
Serotype 8 2234 (n51); 6197 (n51); 6203 (n51)
Serotype 9V 156 (n52)
Serotype 14 9 (n52); 200 (n52); 782 (n51); 876 (n51)
Serotype 15A 1591 (n51)
Serotype 15B/C 199 (n51)
Serotype 19A 199 (n52); 2013 (n51); 2102 (n51); 4904 (n51); 4937 (n51)
Serotype 19F 81 (n51); 320 (n51)
Serogroup 20 235 (n51); 4901 (n51); 5289 (n51)
Serogroup 22 433 (n51)
Serotype 23A 338 (n52)
Serotype 23F 242 (n51) 5273 (n51) 5296 (n51) 6205 (n51) 6212 (n51)
Serotype 34 2832 (n51)
Non-typable 5893 (n51); 6208 (n51)
Non-typable by Pneumotest and mPCR methods.
In bold: novel STs assigned in this study.
One pneumococcal sample did not generate MLST profile.
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(n579), PCV13—74% (n5116) and coverage by PPV-23 would be
86% (n5134).
Clonal diversity
A total of 102 STs were found, of which 38 STs were previously not
reported to the MLST database (Table 1). Twenty-one of the new STs
resulted from a new combination of existing alleles and 17 were due to
new alleles (two isolates shared one new allele and had a different new
allele). Eighteen new sequences for alleles were spread across: aroE
(n51), gdh (n52), gki (n52), recP (n51), spi (n52), xpt (n57) and
ddl (n53).
Our results showed that only few STs were shared between conjug-
ate vaccine (PCV7 or PCV13) and non-conjugate vaccine serotypes
(Table 1 and Figure 2) and that newly identified STs were more pre-
valent in conjugate vaccine serotypes. The clonal diversity was deter-
mined by SID for each serotype (Figure 3). Serotype 19F (n58,
STs58) and non-typable isolates (n55, STs55) were the most diverse
(SID value of 1), followed by serotypes 3 (n518, STs513) and 6B
(n514, STs510) had the SID value 0.96 and 0.95, respectively
(Figure 3). The novel STs were more prevalent among conjugate vac-
cine serotypes 3, 19F and 23F and non-conjugate vaccine serotype 8,
serogroup 15 and in non-typable isolates (Table 1). The SID value
differed only by 0.004 between PCV (n5115, STs571) and non-
PCV (n540, STs531) isolates (Figure 3). ST9, ST81 and ST320 were
found in all three age groups (children under 18, 18–64 and over 64
years). ST9 was consistently found only in serotype 14 whilst ST81 was
found in 6A, 19F and 23F. One of the new STs, ST6197, was identified
in both adult groups (Table 1).
Pneumococcal Molecular Epidemiology Network (PMEN) clones
Thirty-one of the 155 isolates had the sameMLST allelic profiles as 12
globally disseminated antibiotic resistant clones reported to the
PMEN30 (Figure 4). The most common STs were ST81 and ST199;
the same two STs were the only one to be found in more than one
serotype in this dataset (Figure 4). The potential PMEN clones in our
dataset had the same serotypes as multidrug resistant clones reported
to PMEN website and these isolates were found in all age groups
(Table 1). Unfortunately, phenotypic antibiotic susceptibility data
were not available for this set of isolates. The whole genome sequences
were available (Jauneikaite E et al., unpublished data) and used to
identify presence or absence of the specific antibiotic resistance genes
for the seven antibiotics used by the PMEN to identify multidrug
resistant strains: penicillin, erythromycin, clindamycin, tetracycline,
co-trimoxazole, cefotaxime and chloramphenicol. For the clone to be
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Figure 2 goeBURST (PHYLOViZ) analysis of 18 CCs. Population snapshot based on goeBURST analysis of 155 pneumococcal isolates. 18 CCs were formed. Each
colour represents a different serotype.
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classified as an international antibiotic resistant pneumococcal clone,
the isolate needs to be resistant to one or more of antibiotics of wide
clinical use.30 Sixteen isolates had all three pbp2A, pbp1A and pbp1B
alleles present, the other ten isolates carried either pbpX, pbp2X and
pbp2B or a combination of any two of these alleles (Jauneikaite E et al.,
unpublished data). In total, eleven isolates also had macrolide resist-
ance alleles (mefA, emrB and msrD) (Jauneikaite E et al., unpublished
data). Additionally, seven isolates had chloramphenicol resistance
allele cat(pC194) and sixteen isolates had tetracycline resistance
allele—tet(M) (Jauneikaite E et al., unpublished data). Overall, every
potential PMEN clone had resistance alleles to at least three different
antibiotics.
goeBURST analysis
goeBURST27 showed the results for all 155 isolates (Figure 2). Sixty-
two out of 102 were singletons and 18 clonal complexes (CCs) were
formed (Figure 2).
Comparative eBURST26 of our 155 isolates against the whole
S. pneumoniaeMLST database showed that all of the 102 STs fall into
CCs and were distributed across the eBURST diagram of the whole
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S. pneumoniaeMLST database. The highest number of STs (n511, 18
isolates) fell into CC156. Four CCs consisted of STs found in this
study, of which one CC was solely formed by ST6212 and ST5273.
No singletons were found (last checked 31 May 2013).
Seven of the 18 CCs consisted of two or more different serotypes
with different STs that differ just by one locus (Figure 2). ST81 and
ST199 were from diverse serotypes (Figure 2).
DISCUSSION
In this 2009–2010 study, undertaken in the first year of PCV7
implementation in Singapore, we found that 74% of the serotypes
isolated are included in PCV13 and 38% are included in PCV7. The
fact that only 38% of isolates identified were PCV7 serotypes (plus
serotype 6A) suggests that these serotypes represent a smaller pro-
portion of potential IPD-causing serotypes and that vaccination
with the PCV13 may increase protection against IPD. The low
percentage of PCV7-related serotypes could be due to the herd
immunity effect, as reported in the United States31,32 and United
Kingdom,33 however, considering that the uptake of PCV7 is low in
Singapore.15 Also, minimal changes were reported in the incidences
of IPD in children in Singapore after early stages of PCV7 imple-
mentation during 2005–2010 by Thoon et al.34
Within our dataset, the most common serotypes were 3, 6B, 7F, 8,
14, 19A, 19F and 23F. All but serotype 8—are included in PCV13.
PCV13 was implemented in the childhood immunization schedule
in Singapore in December 2011. The National Public Health
Laboratory and KK Women & Children’s Hospital in Singapore,
reported to theMinistry ofHealth in Singapore that themost common
pneumococcal serotypes found in IPD cases in year 2010–2011 in
paediatric cases (exact age not reported) were serotypes 19A (40%),
14 (15%) and 6B (13%), while in adults, the diversity of serotypes
found was greater and the most common found were: serotype 3
(13%), 14 (10%), 19A (10%) and 8 (10%).10 Later, Thoon et al.34
reported the changes in most common serotypes found in children
population in KK Women & Children’s hospital, highlighting the
increase in invasive disease caused by serotypes 19A. In our dataset,
only 12 IPD isolates from children under the age of five years old were
available, most common being 6B, 19A and 14. These data are in
agreement with previous reports from the region.12,35
Most of the 102 STs identified here have been reported previously
on the MLST website; however, a substantial number (n538, 37%)
were new STs. Serotype 19A was the most common serotype found in
our study. One pneumococcal isolate ST32019A was isolated from
pleural fluid sample from a patient under the age of five years, who
was vaccinated with four doses of PCV7 which does not include sero-
type 19A. Unfortunately, no further clinical information was available
for this patient. It has been reported that ST320 is commonly assoc-
iated with serotype 19A and this clone is widely spread across the
world.26 The penicillin resistant ST320 serotype 19A clone was com-
monly found to cause IPD in children in the USA between 2005 and
2007.36 Another common clone of serotype 19A is ST199. This ST199
is reported as the major genotype for penicillin susceptible invasive
serotype 15B/C and intermediately penicillin resistant serotype 19A in
the United States.36 In our study, one ST199 isolate was serotype 15B/
C in the adult group over 64 years old. None of the other serotype 19A
isolates belonged to any of the new ST or other major antibiotic
resistance CCs. Here we identified four isolates as ST32019A and two
isolates as ST19919A. ST32019A was reported to be the dominant clone
in Asian countries,37 but an increase in different and new (previously
not reported to MLST database) genotypes are also seen.37
We have demonstrated considerable genetic diversity among
Singaporean IPD isolates using serotyping and MLST. Approximately
half of all novel IPD clones identified in this study were non-conjugate
vaccine serotypes. There is scarce information available on themolecular
epidemiology of pneumococcal disease not only from Singapore, but
also from other South East Asian countries. Increasing availability and
affordability of high throughput sequencing technologies has the poten-
tial to provide more information on circulating strains in different
countries and will help to map out possible transmission routes globally.
In order to evaluate the true effects of pneumococcal conjugate
vaccines in Singapore, studies investigating the molecular epidemi-
ology of disease-causing pneumococci are in progress. However,
pneumococcal carriage is a precursor to pneumococcal diseases; there-
fore, we would strongly encourage pneumococcal carriage studies to
be undertaken in order to assess the circulating pneumococcal popu-
lation in Singapore.
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